ALNY Jan 2025 160.000 put
- Business Wire
Alnylam Issues 2023 Corporate Responsibility Report
CAMBRIDGE, Mass., May 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition expands data disclosures across each pillar and highlights examples of the company’s commitment to ensuring patient access, reducing health inequities, and being a responsible stewar
- Simply Wall St.
The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) just released its latest first-quarter results and things are looking...
- Insider Monkey
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75. ALNY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
